Tularik to Present Credit Suisse First Boston Health Care Conference
Thursday November 7, 6:06 pm ET
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 7, 2002--Tularik Inc. (Nasdaq:TLRK - News) announced that David V. Goeddel, Ph.D., Tularik's chief executive officer, is scheduled to present at the Credit Suisse First Boston Health Care Conference at The Arizona Biltmore Resort & Spa in Phoenix, Ariz., on Thursday, Nov. 14, 2002, beginning at 3:15 p.m. Pacific Standard Time.
Tularik's presentation will be webcast live and may be accessed at the Company's URL www.tularik.com under the Investor Relations tab. A replay of the presentation will be available for 30 days.
About Tularik
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has three drug candidates in clinical trials, T487 for the treatment of inflammatory diseases, and T67 and T607 for the treatment of cancer. T67 is moving into a pivotal Phase 2/3 study for the treatment of Hepatocellular Carcinoma (HCC) and T607 is in four Phase 2 trials for the treatment of HCC, non-Hodgkin's lymphoma, ovarian cancer and gastric cancer. T487, for the treatment of inflammatory diseases, is in a Phase 1 trial to evaluate safety. For more information, visit Tularik's Internet website at www.tularik.com.
--------------------------------------------------------------------------------
Contact:
Tularik Inc.
Traci McCarty, 650/825-7182 |
